Kevin Rolland

Equity Capital Markets

Kevin joins Bryan, Garnier & Co as Vice President – Equity Capital Markets.

Prior to joining the firm, Kevin spent 6 years in the Investment Banking division of TP ICAP where he had the opportunity to execute several ECM & DCM deals in various sectors including Software, Gaming, Real Estate, Retail and Technology. Prior to this, he spent 4 years as an M&A associate for an independent corporate finance boutique in Paris and London, DragonKnight Advisors. Kevin holds a Master’s degree in Banking & Corporate Finance from Toulouse Business School.

Will Jungman

Equity Capital Markets

Will joins Bryan, Garnier & Co as Vice President – Equity Linked Solutions.

Prior to joining the firm, Will served as consultant to Bryan Garnier during which he executed several ECM and DCM deals across the Technology and Healthcare sectors. Will has a structured finance background, having spent five years working with UK property developers and operators, including SquarestoneHUB in London, as well as in finance for Georgia-Pacific, a major American consumer product company. Prior to his career in structured finance, he also spent 2.5 years with Deloitte Consulting’s Finance practice. Will holds an MBA from the Wharton School and a Bachelor’s in Economics from the University of Virginia.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.